Bristol-Myers Squibb Company stock (US0897961004): Dividend paid May 1

Bristol-Myers Squibb Company paid a quarterly dividend of $0.63 per share on May 1, 2026, to shareholders of record on April 2. This equates to an annualized yield of 4.5%, with a payout ratio of 70.79%, according to recent filings.

Bristol-Myers Squibb Company paid its latest quarterly dividend of $0.63 per share on Friday, May 1, 2026, to shareholders of record as of Thursday, April 2, 2026. This payment represents an annualized dividend of $2.52, delivering a yield of 4.5% based on recent share pricing, according to MarketBeat as of 05/14/2026.

The company's dividend payout ratio stands at 70.79%, indicating a balanced approach to returning capital to investors while retaining funds for operations and growth. Bristol-Myers Squibb, listed on the NYSE under ticker BMY, maintains a strong position in the US biopharmaceutical market, where its therapies address serious diseases.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bristol Myers Squibb Company
• Sector/industry: Biopharmaceuticals
• Headquarters/country: Princeton, New Jersey, USA
• Core markets: Global, with strong US presence
• Key revenue drivers: Oncology, immunology, cardiovascular drugs
• Home exchange/listing venue: NYSE (BMY)
• Trading currency: USD

Bristol-Myers Squibb Company: core business model

Bristol-Myers Squibb Company is a global biopharmaceutical firm headquartered in Princeton, New Jersey, dedicated to discovering, developing, and delivering innovative medicines for serious illnesses such as cancer, cardiovascular disease, and immunology disorders. The company operates through a research-driven model, investing heavily in R&D to advance its pipeline of therapies. Its portfolio includes blockbuster drugs like Opdivo for oncology and Eliquis for anticoagulation, which generate substantial revenue streams.

This model emphasizes strategic partnerships and acquisitions to bolster its drug development capabilities. For US investors, Bristol-Myers Squibb's NYSE listing provides direct access to a leader in the biotech sector, which plays a pivotal role in the US healthcare economy.

Main revenue and product drivers for Bristol-Myers Squibb Company

Key revenue drivers include its oncology franchise, led by PD-1 inhibitor Opdivo, alongside immunology products like Orencia and cardiovascular staple Eliquis, co-marketed with Pfizer. In the quarter ending September 2024, the company reported earnings of $1.80 per share, surpassing Zacks Consensus estimates of $1.49, according to Zacks as of 07/03/2025. These products target high-demand areas in the US market, where aging demographics drive demand.

The firm's diversified portfolio mitigates risks from patent expirations, with ongoing pipeline advancements in areas like Alzheimer's through collaborations such as the expanded pact with Tempus for AI-driven oncology and neurology trials, as noted in recent updates from StockTitan.

Industry trends and competitive position

The biopharma industry faces trends like rising demand for precision medicine and AI integration in drug discovery, where Bristol-Myers Squibb competes with peers like Pfizer and Merck. Its market cap of $115.17 billion, with a 12-month range of $42.52 to $62.89, reflects resilience amid sector volatility, per MarketBeat as of 05/14/2026. The company's US-centric revenue exposure makes it relevant for domestic portfolios.

Why Bristol-Myers Squibb Company matters for US investors

As a NYSE-listed biopharma giant with headquarters in the US, Bristol-Myers Squibb offers exposure to the robust American healthcare sector, which benefits from strong Medicare and private insurance demand. Its dividend consistency appeals to income-focused investors tracking S&P 500 components.

Conclusion

Bristol-Myers Squibb Company's recent dividend payment underscores its commitment to shareholder returns amid ongoing innovation in biopharma. With a solid yield and diversified revenue, the stock remains a notable name in US portfolios, though market dynamics warrant monitoring. Financial metrics from Q3 2024 earnings highlight operational strength.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.